The impact of ergotamine-induced headache and ergotamine withdrawal on information processing.
Ergotamine abuse and subsequent ergotamine-induced headache is a common problem in the pharmacological treatment of migraine and other headache types; often, withdrawal therapy is necessary. This study investigated whether ergotamine abuse affects information processing and whether withdrawal therapy can lead to an improvement of information processing. We designed a standardized neurophysiological retrospective (ergotamine abuse) and prospective (ergotamine withdrawal) study in a supraregional headache outpatient clinic. Seventy-one patients abusing ergotamine derivatives with subsequent daily headache were enrolled and compared to 36 migraine patients without ergotamine intake and 36 healthy subjects. Information processing was evaluated by latencies and amplitudes of visually evoked event-related potentials (ERP) before and after ergotamine withdrawal therapy. P3 latency of the ERP was significantly increased in ergotamine abuse (442 +/- 45 ms) versus migraine (415 +/- 40 ms) and healthy subjects (410 +/- 33 ms), there was no difference between ergotamine tartrate and dihydroergotamine abuse. The migraine specific loss of habituation in information processing as measured by P3 latency could not be observed in migraine patients with ergotamine abuse. After successful withdrawal therapy in 36 patients, the abnormally prolonged P3 latency was significantly shortened (452 +/- 47 ms versus 433 +/- 30 ms; P < 0.004). Our findings imply that information processing is impaired by ergotamine abuse and can be improved but not normalized after withdrawal therapy. Furthermore, our data provide strong evidence that ergotamine, besides its peripheral effects, has a central mode of action.
Evers
S
S
Department of Neurology, University of Münster, Germany. everss@uni-muenster.de
Schmidt
F
F
Bauer
B
B
Voss
H
H
Grotemeyer
K H
KH
Husstedt
I W
IW
D000316:Adrenergic alpha-Agonists / Q000009:adverse effects / Q000494:pharmacology; D000328:Adult; D003072:Cognition Disorders / Q000139:chemically induced; D004878:Ergotamine / Q000009:adverse effects / Q000494:pharmacology*; D005071:Evoked Potentials / Q000187:drug effects*; D005260:Female; D006261:Headache / Q000139:chemically induced / Q000523:psychology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012189:Retrospective Studies; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology / Q000523:psychology; D019966:Substance-Related Disorders
D000316:Adrenergic alpha-Agonists; D004878:Ergotamine